318 related articles for article (PubMed ID: 36562884)
1. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
2. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
3. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
4. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.
Kimura T; Tsutsumi K; Taoka M; Saito T; Masuda-Suzukake M; Ishiguro K; Plattner F; Uchida T; Isobe T; Hasegawa M; Hisanaga SI
J Biol Chem; 2013 Mar; 288(11):7968-7977. PubMed ID: 23362255
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
6. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
Moore KBE; Hung TJ; Fortin JS
Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
[TBL] [Abstract][Full Text] [Related]
7. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
8. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
9. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
[TBL] [Abstract][Full Text] [Related]
10. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
11. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
12. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
13. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
15. TBK1 interacts with tau and enhances neurodegeneration in tauopathy.
Abreha MH; Ojelade S; Dammer EB; McEachin ZT; Duong DM; Gearing M; Bassell GJ; Lah JJ; Levey AI; Shulman JM; Seyfried NT
J Biol Chem; 2021; 296():100760. PubMed ID: 33965374
[TBL] [Abstract][Full Text] [Related]
16. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
17. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
[TBL] [Abstract][Full Text] [Related]
18. The role of tau in Alzheimer's disease and related disorders.
Medeiros R; Baglietto-Vargas D; LaFerla FM
CNS Neurosci Ther; 2011 Oct; 17(5):514-24. PubMed ID: 20553310
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tau-induced neurodegeneration.
Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
[TBL] [Abstract][Full Text] [Related]
20. A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.
García-Escudero V; Ruiz-Gabarre D; Gargini R; Pérez M; García E; Cuadros R; Hernández IH; Cabrera JR; García-Escudero R; Lucas JJ; Hernández F; Ávila J
Acta Neuropathol; 2021 Jul; 142(1):159-177. PubMed ID: 33934221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
